ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · EFO_0803536

multiple sclerosis symptom measurement

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. multiple sclerosis symptom measurement. Diseases, record EFO_0803536. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0803536

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
multiple sclerosis symptom measurement
Open Targets ID
EFO_0803536
Other names
Disseminated Sclerosis, MS, MS (Multiple Sclerosis), MULTIPLE SCLEROSIS ACUTE FULMINATING, Sclerosis, Disseminated, Sclerosis, Multiple, multiple sclerosis
Highest stage of its drugs
Approval, for 40 of its 279 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD

Source Open Targets

Drugs279

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
INTERFERON BETA-1ACHEMBL1201562ProteinApprovalDailyMed, EMA Human Drugs, PMDA and TTD958483Drugs and targets
OCRELIZUMABCHEMBL2108041AntibodyApprovalDailyMed, EMA Human Drugs and TTD817878Drugs and targets
FINGOLIMODCHEMBL314854Small moleculeApprovalEMA Human Drugs and TTD555353Drugs and targets
NATALIZUMABCHEMBL1201607AntibodyApprovalDailyMed, EMA Human Drugs, FDA, PMDA and TTD595252Drugs and targets
DIMETHYL FUMARATECHEMBL2107333Small moleculeApprovalDailyMed, EMA Human Drugs, PMDA and TTD615151Drugs and targets
INTERFERON BETA-1BCHEMBL1201563ProteinApprovalDailyMed, EMA Human Drugs and TTD565049Drugs and targets
GLATIRAMER ACETATECHEMBL1201507Small moleculeApprovalDailyMed, PMDA and TTD534949Drugs and targets
TERIFLUNOMIDECHEMBL973Small moleculeApprovalDailyMed, EMA Human Drugs and TTD423939Drugs and targets
DALFAMPRIDINECHEMBL284348Small moleculeApprovalDailyMed, EMA Human Drugs and TTD363130Drugs and targets
OFATUMUMABCHEMBL1201836AntibodyApprovalDailyMed and PMDA282626Drugs and targets

1 to 10 of 279

See all 279 drugs

Targets352

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
NR3C1Glucocorticoid receptor17Glucocorticoid receptor agonistApprovalhttps://conductscience.org/library/genes/2908Drugs and targets
S1PR1Sphingosine 1-phosphate receptor10
Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent; Sphingosine 1-phosphate receptor modulator
Approvalhttps://conductscience.org/library/genes/1901Drugs and targets
S1PR5Sphingosine 1-phosphate receptor6Sphingosine 1-phosphate receptor 5 modulator; Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent; Sphingosine 1-phosphate receptor modulatorApprovalhttps://conductscience.org/library/genes/53637Drugs and targets
SCN10ASodium channel alpha subunit6Sodium channel alpha subunit blockerPhase 2https://conductscience.org/library/genes/6336Drugs and targets
SCN11ASodium channel alpha subunit6Sodium channel alpha subunit blockerPhase 2https://conductscience.org/library/genes/11280Drugs and targets
SCN1ASodium channel alpha subunit6Sodium channel alpha subunit blockerPhase 2https://conductscience.org/library/genes/6323Drugs and targets
SCN2ASodium channel alpha subunit6Sodium channel alpha subunit blockerPhase 2https://conductscience.org/library/genes/6326Drugs and targets
SCN3ASodium channel alpha subunit6Sodium channel alpha subunit blockerPhase 2https://conductscience.org/library/genes/6328Drugs and targets
SCN4ASodium channel alpha subunit6Sodium channel alpha subunit blockerPhase 2https://conductscience.org/library/genes/6329Drugs and targets
SCN5ASodium channel alpha subunit6Sodium channel alpha subunit blockerPhase 2https://conductscience.org/library/genes/6331Drugs and targets

1 to 10 of 352

See all 352 targets

Trials877

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 29 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01585298STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)Phase 46,9982019-09-23Multiple SclerosisFINGOLIMODIts record names the diseaseClinicalTrials.gov
NCT01201356Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisPhase 34,1252019-11-07Relapsing Forms of Multiple SclerosisFINGOLIMODIts record names the diseaseClinicalTrials.gov
NCT03193866COMparison Between All immunoTherapies for Multiple Sclerosis.3,5262025-04-20Relapsing-remitting Multiple SclerosisRITUXIMABIts record names the diseaseClinicalTrials.gov
NCT02576717A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisPhase 32,4942024-01-30Multiple SclerosisOZANIMODIts record names the diseaseClinicalTrials.gov
NCT01707992The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)Phase 32,1992019-03-13Multiple SclerosisLAQUINIMODIts record names the diseaseClinicalTrials.gov
NCT01064401Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisPhase 31,8412016-07-11Relapsing-Remitting Multiple SclerosisDACLIZUMAB, INTERFERON BETA-1AIts record names the diseaseClinicalTrials.gov
NCT00835770BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)Phase 31,7362020-12-31Relapsing-Remitting Multiple SclerosisDIMETHYL FUMARATEIts record names the diseaseClinicalTrials.gov
NCT01665144Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)Phase 31,6512018-10-31Secondary Progressive Multiple SclerosisSIPONIMODIts record names the diseaseClinicalTrials.gov
NCT00906399Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisPhase 31,5162014-09-19Relapsing Multiple SclerosisPEGINTERFERON BETA-1AIts record names the diseaseClinicalTrials.gov
NCT01797965Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019Phase 31,5012019-12-04Relapsing-Remitting Multiple Sclerosis, Multiple SclerosisDACLIZUMABIts record names the diseaseClinicalTrials.gov

1 to 10 of 877

See all 877 trials

Comparisons in its trials277

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
IFN Beta-1a 30 mcg vs DAC HYP 150 mg: serious adverse events194 of 922221 of 9191,841NCT01064401Trial comparisons
BG00012 240 mg BID vs BG00012 240 mg TID: Number of Participants With Treatment-Emergent Adverse Events (AEs)824 of 868814 of 8681,736NCT00835770Trial comparisons
BG00012 240 mg BID vs BG00012 240 mg TID: deaths from any cause5 of 8686 of 8681,736NCT00835770Trial comparisons
BG00012 240 mg BID vs BG00012 240 mg TID: serious adverse events279 of 868272 of 8681,736NCT00835770Trial comparisons
Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry887 of 891501 of 5041,395NCT01707992Trial comparisons
Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Hematology Values
886 of 891499 of 5041,395NCT01707992Trial comparisons
Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active-Treatment Phase: Number of Participants With AEs442 of 891241 of 5041,395NCT01707992Trial comparisons
Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active-Treatment Phase: Number of Participants With Clinically Significant Vital Signs Abnormalities17 of 8917 of 5041,395NCT01707992Trial comparisons
IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) vs DAC HYP 150 mg (301) /DAC HYP 150 mg (303): Number of Participants Who Are Free From Disease Activity in the 205MS303 Treatment Period9 of 5977 of 6061,203NCT01797965Trial comparisons
IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) vs DAC HYP 150 mg (301) /DAC HYP 150 mg (303): Number of Participants With Relapse in the 205MS301-303 Combined Study Period339 of 597261 of 6061,203NCT01797965Trial comparisons

1 to 10 of 277

See all 277 comparisons in its trials

Papers from its trials597

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
39307151RESULT2PubMed
38335474RESULT1PubMed
37626477RESULT1PubMed
36689214RESULT1PubMed
36418156RESULT1PubMed
36126241RESULT1PubMed
35701185RESULT1PubMed
33045496RESULT2PubMed
31492652RESULT1PubMed
31169568RESULT1PubMed

1 to 10 of 597

See all 597 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0803536

GET https://conductscience.org/api/diseases/v1/EFO_0803536/drugs?page=2

API referenceFor AI assistants